BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rapcabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rapcabtagene autoleucel\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03960840-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT03960840)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Phase I/II Study o
 f Rapcabtagene Autoleucel in CLL\, 3L+ DLBCL\, r/r ALL and 1L HR LBCL\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03960840
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581198-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06581198)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2\, Lupus Nephritis.\nStudy: A 
 Study of Rapcabtagene Autoleucel in Active\, Refractory Systemic Lupus Ery
 thematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)\nEs
 timated primary completion: 14 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06581198
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443137-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rapcabtagene autoleucel: Phase 1 readout est. (NCT07443137)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1.\nStudy: CAR-T ceLL for Eradi
 cation of Active Residual Disease in LBCL (CLEAR-1 Study)\nEstimated prima
 ry completion: August 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07443137
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07048197-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT07048197)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: A Study to Assess 
 Safety\, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autole
 ucel in Rheumatoid Arthritis and Sjogren's Disease\nEstimated primary comp
 letion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rapcabtagene-autoleucel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07048197
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655896-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06655896)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study Evalua
 ting Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous System
 ic Sclerosis\nEstimated primary completion: 30 November 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06655896
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665256-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20290309
DTEND;VALUE=DATE:20290310
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06665256)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study of Rap
 cabtagene Autoleucel in Myositis\nEstimated primary completion: 9 March 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rapcabtagene-auto
 leucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06665256
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868290-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20290607
DTEND;VALUE=DATE:20290608
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06868290)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study Evalua
 ting Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
 \nEstimated primary completion: 7 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06868290
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704269-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06704269)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Study to Assess Sa
 fety\, Efficacy\, and Cellular Kinetics of YTB323 in Generalized Myastheni
 a Gravis\nEstimated primary completion: 26 October 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06704269
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675864-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06675864)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Open-label\, Multi
 -center\, Phase I/II Study to Assess Safety\, Disease Progression and Cell
 ular Kinetics Following YTB323 Administration in Participants With Non-act
 ive Progressive Multiple Sclerosis (PMS)\nEstimated primary completion: 14
  June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rapcabtag
 ene-autoleucel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06675864
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06617793-11270@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20300807
DTEND;VALUE=DATE:20300808
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06617793)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: An Open-label Stud
 y to Assess the Safety\, Efficacy\, and Cellular Kinetics of YTB323 in Rel
 apsing Multiple Sclerosis\nEstimated primary completion: 7 August 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066
 17793
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
